Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Argus Pharmaceuticals
Patients who have completed protocol FDA 103B are offered the option of receiving extended maintenance. Patients who have received no prior ddI are treated either with intravenous nystatin alone (at the same dose level administered in FDA 103B) or with a regimen of intravenous nystatin and ddI alternating on 3-week cycles. Treatment continues for 12 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
Completed 12 weeks of therapy with intravenous nystatin on protocol FDA 103B.
No evidence of toxicity or progression of disease on protocol FDA 103B. (See protocol FDA 103B for initial entry requirements.)
Active drug or alcohol abuse.
Clareo Health | A Study of Nystatin in HIV-Infected Patients
